Clinical trials
Pathologic Complete Response trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
28 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 1 |
| 2008 | 2 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 2 |
| 2014 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Active, not recruiting | 5 |
| Withdrawn | 3 |
| Recruiting | 3 |
| Terminated | 3 |
| Unknown status | 2 |
| Suspended | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| M.D. Anderson Cancer Center | 2 |
| Sellas Life Sciences Group | 2 |
| Yale University | 2 |
| Armando Giuliano | 1 |
| AstraZeneca | 1 |
| BioFire Diagnostics, LLC | 1 |
| Celgene | 1 |
| Coronado Biosciences, Inc. | 1 |
| Doc Lab Inc | 1 |
| Duke University | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pathologic Complete Response | 28 |
| Leukemia, Myeloid, Acute | 9 |
| Breast Neoplasms | 4 |
| Leukemia | 3 |
| COVID-19 | 2 |
| Neoplasms | 2 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 |
| Triple Negative Breast Neoplasms | 2 |
| Candidiasis | 1 |
| Carcinoma, Non-Small-Cell Lung | 1 |
Trials
Showing 1 to 25 of 28. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.